MedMira receives European approval for Syphilis/HIV Multiplex rapid test
MedMira, a developer of rapid diagnostic technology platforms and testing solutions, has received the CE Mark on its syphilis/HIV rapid test (Multiplo TP/HIV). This approval enables the company to market and distribute the multiplex rapid test throughout the European Union (EU), where syphilis and HIV rates are on the rise, and in global markets that accept CE Mark products.
The Multiplo test uses just a small sample of fingerprick or venipuncture whole blood, serum or plasma and enables easy and accurate screening for both Treponema pallidum (TP), the bacteria causing syphilis, and HIV simultaneously. MedMira’s technology is a game-changer for point-of-care treatment, as it provides instant results, whereas established technology takes hours to deliver results.
Read more about the announcement here.